A randomized, double-blind, parallel-group, single ‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men

ConclusionThis study demonstrated PK bioequivalence of INTP24 to US-bevacizumab and EU-bevacizumab in healthy male subjects and showed similar safety and immunogenicity profiles across the treatment groups.

http://link.springer.com/10.1007/s00280-020-04111-2

Source: Cancer Chemotherapy and Pharmacology - July 4, 2020 Category: Cancer & Oncology Source Type: research